🚨 Few spots left!
Join the 7th International Conference on #Cytokines in #Cancer
📅 May 17–22, 2026
📍 Sissi, Crete, Greece
Topics: cytokines & cell communication, inflammation and cancer, #tumormicroenvironment, #irAEs, and therapies.
Register: www.aegeanconferences.org/src/App/conf...

Yes to low-dose & shorter #immunotherapy regimens! We need more attention to #irAEs toxicity, including #financial toxicity for all patients. @ascocancer.bsky.social @ascopost.bsky.social @cityofhopecologne.bsky.social Join autoimmunecancer.org to help us do more for #patients!

Consequences of adverse events in cancer immunotherapy combinations – a comprehensive real-world analysis Immune checkpoint inhibitors (ICIs) are pivotal in systemic anticancer therapy. The aim of the study was to investigate incidence, severity and consequences of immune-related adverse events (irAEs)...

How does #toxicity from #immunotherapy affect the real world patient?
Northern Norway we investigated #irAES in different #ICI combinations, with 40% of the patients experienced an #CTCAE grade 2 or more #irAE, leading to hospitalization or becoming chronic.

www.tandfonline.com/doi/full/10....

Treat #irAEs associated with #Bispecifics and T cell Engagers! Access the latest updates on #cytokine release syndrome and #immune effector cell-associated neurotoxicity during our free #webinar Dec. 17. Learn more and register: https://ow.ly/GByq50XgXSH

ASPIRE August Newsletter

Check out the Aug 2025 #ASPIRE newsletter to hear the latest in #irAEs. Do not miss our quarterly case conference Tues, Aug 19th at 5:30pm CST. @ascocancer.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social @kmittalmd.bsky.social mailchi.mp/759095cedbb0...

ICI Retreatment After Severe Toxicities Yields Promising Responses - Oncology Nurse Advisor Results of a retrospective study demonstrated that retreatment with ICIs after severe immune-related adverse events could result in good response for select patients.

Retreatment with ICIs following severe #irAEs demonstrated acceptable safety and meaningful antitumor activity, suggesting viability in carefully selected patients.

bit.ly/4liVYA5

#adverseevents

Frequency and Severity of Common irAEs Play Key Role in Patient Education Needs - Oncology Nurse Advisor A retrospective review of patients with cancer treated with ICIs identified patient education needs by frequency and severity of irAEs.

A key part of managing immune-related #adverseEvents is adequate patient education regarding disease triggers, incidence, and severity. Published in @ascocancer.bsky.social journal JCO Oncology Practice.

bit.ly/4kYVaAz

#irAEs

Our farewell to #EULAR25 is a poster about checkpoint inhibitors associated myositis. It's a fast & furious condition, in which acting quickly, knowing the treatment options and good coordination with other specialist makes all the difference! #irAEs

Advance your training in #computational #immuno-oncology and stay abreast of the latest technologies - register today for the #SITC #NCI #Non-invasive #Biomarkers for #irAEs Webinar on Wednesday, June 18, 2025. Register for this free-to-attend digital event: sitcancer.org/CompIO

-ICIs are amazing for cancer treatment (Whee!).
-But they can cause irAEs like PMR (Whoo...).
-But most can be safely managed (Whee!).
-But you mustn't overdo it with the IS or it may impact the antineoplastic effect (Whoo...).

So come for a talk about balancing the Whees & Whoos! #EULAR25 #irAEs

Dr @mazietsangmd.bsky.social eloquently ties together the 3 discussions of impact of #irAEs on clinical practice. She ends with a touching self portrait of a patient who died of an #irAE #pallonc #supponc #ASCO25

@ascocancer.bsky.social
@ericroeland.bsky.social
@darcyburbage.bsky.social

🌟 Got questions about #irAEs? 🤔 What about tumor deposits in the lung or liver—do they heighten the risk? Recent retrospective data from hospitalized patients suggests an association 🚨 jitc.bmj.com/content/13/5... #ASPIRE @aspire-cop.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social

ASPIRE May Newsletter

Presenting our May #ASPIRE newsletter mailchi.mp/0ec7836f3ddc... Check out our #ASCO25 COP meeting #irAEs @ascocancer.bsky.social @sitcancer.bsky.social @myesmo.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @eladsharonmd.bsky.social @oncoalert.bsky.social

Interested in #irAEs? Join the Alliance for Support and Prevention of Immune-Related Adverse Events #ASPIRE
Follow QR code or Google Form docs.google.com/forms/d/1zfl...
@funchainmd.bsky.social
@kerryreynoldsmd.bsky.social
@kmittalmd.bsky.social @ascocancer.bsky.social
@oncodaily.bsky.social

I’m in! #irAEs #OncSky #ASPIRE @rsedhom.bsky.social @kmittalmd.bsky.social @pallonccop.bsky.social

Bluesky

I spy #irAE extraordinaire @kerryreynoldsmd.bsky.social. Welcome to BlueSky! Uniting our #OncSky and subspeciality community to improve the lives of people experiencing #irAEs @ascocancer.bsky.social @funchainmd.bsky.social @kmittalmd.bsky.social @eladsharonmd.bsky.social @mazietsangmd.bsky.social

Understanding predictive biomarkers with #immunotherapy is critical. Equally is there an opportunity to codevelop strategies that also predict and/or monitor toxicity? #irAEs #IOTOX #ASCO2025 @funchainmd.bsky.social @eladsharonmd.bsky.social @kmittalmd.bsky.social @mazietsang.bsky.social

Smartsheet Forms

Protocol for the @ascocancer.bsky.social guideline update on management of immune-related adverse effects available for open comment through March 19 #ASCOguidelines #irAEs #MedSky #OncSky #SuppOnc app.smartsheet.com/b/form/e3689...

Are you a European clinician🇪🇺 who treats pts with IO & manages #irAEs? Join us in creating a pan-European vision for #irAE care🌍

Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_...

@oncoalert.bsky.social

Targeting Molecular Pathways to Control ICI Toxicities - OncoDaily Targeting Molecular Pathways to Control ICI Toxicities / cancer, Celentyx, fight against cancer, Global fight against cancer, ICI, Immune Checkpoint

Targeting Molecular Pathways to Control ICI Toxicities
@drrobinreschke.bsky.social

oncodaily.com/science/216594

#Cancer #Celentyx #ICI #Immunology #CellPress #irAEs #OncoDaily #Oncology #Medicine #Health

Detection of Patient-level Immunotherapy-related Adverse Events (irAEs | POR Developing an artificial intelligence model to detect immunotherapy -related adverse events (irAEs) from clinical narratives of electronic health records (EHRs)

New publication about the use of #AI in helping to identify #irAEs for retrospective reviews / real world data #immunotherapy @osucccjames.bsky.social @osuwexmed.bsky.social Detection of Patient-level Immunotherapy-related Adverse Events (irAEs | POR www.dovepress.com/articles.php...